

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF      ART UNIT: 1625  
COLLINGWOOD, STEPHEN PAUL ET AL.      EXAMINER: CHANG, CELIA C  
INTERNATIONAL APPLICATION NO: PCT/EP2004/006795  
FILED: JUNE 23, 2004  
U.S. APPLICATION NO: 10/561366  
35 USC §371 DATE: MAY 15, 2006  
FOR: PIPERIDINIUM AND PYRROLIDINIUM DERIVATIVES AS LIGANDS  
FOR THE MUSCARINIC M3 RECEPTOR

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

/Cozette M. McAvoy/

Novartis Pharmaceuticals Corporation  
One Health Plaza, Bldg. 101  
East Hanover, NJ 07936  
(862) 778-9273  
Date: May 26, 2010

Cozette M. McAvoy  
Attorney for Applicant  
Reg. No. 60,457